Friday, September 23, 2022

Managing 340B, Medicaid Drug Discounts: Technology for Collaboration – Anywhere, Anytime

Today’s guest post comes from Lindsey Alves, Vice President of Customer Success at Kalderos.

Lindsey describes the challenges facing remote workers who manage government-managed drug discount programs. As she explains, all drug discount stakeholders require novel technology-enabled collaboration tools.

To learn more, register for Kalderos’ panel discussion, The Dreaded Duplicate Discounts: Collaborating in the New Hybrid Working Landscape. You can also schedule a meeting with Kalderos at the Informa Connect Medicaid Drug Rebate Conference, October 13, 2022, in Chicago.

Read on for Lindsey’s insights.

Managing 340B, Medicaid Drug Discounts: Technology for Collaboration – Anywhere, Anytime
By Lindsey Alves, Vice President, Customer Success, Kalderos

Look around. Chances are, you are a participant in a quiet revolution. You are working anywhere you want—your home, a local coffee shop, the library or, perhaps, at one of the many coworking spaces that have sprouted up across the nation.

Working remotely has become a mainstay in corporate America, with many organizations shifting to a fully remote or hybrid model amid the COVID-19 pandemic. The idea of the workplace has shifted so dramatically in the last two-and-a-half years that entire industries are forced to rethink how they operate.

According to data from the McKinsey American Opportunity Survey, 58% of Americans report having the opportunity to work from home at least one day a week. Another 38% report having the option to work from home for five days a week. What makes these figures stand out is that the respondents represent work in all types of roles, including healthcare jobs that are typically office-based, where employees spend most of their time in front of a computer monitor or on a phone.

Like many other industries, healthcare is experiencing a transformation in the modern workforce, with all signs pointing toward a level of flexibility never before seen in traditional office settings. Digital technology is accelerating this remote-work dynamic. Telehealth, remote patient monitoring and artificial intelligence and analytics platforms have grown in popularity because they have the potential to optimize methodologies, improve patient outcomes, reduce human error and lower costs.

Unfortunately, not all sectors of the healthcare industry have had such ease evolving their workflows in these hybrid times. Many stakeholders in the Drug Discount Management space continue to rely on antiquated processes, such as emails, phone calls and combining Excel files, to manage the 340B and Medicaid programs and ensure compliance with federal regulations. Despite their best efforts, communication between parties is either spotty or nonexistent. Data sharing is complex, and the propensity for human error is high. Transparency is hard to come by. The fallout: drug discount programs fail to function as intended—to stretch scarce federal resources, reach more patients and provide more comprehensive services.


The good news is that Kalderos is dedicated to building relationships among all drug discount stakeholders, making it easier for those transitioning to today’s remote work environment. Our technology bridges critical gaps in collaboration and communication to ensure all parties are on the same page.

We’ve developed the world’s first platform for Drug Discount Management, powered by a modern data warehouse of more than 20 third-party sources that can process more than 100 million drug discount claims per hour. Our platform creates greater transparency and collaboration among manufacturers, covered entities and state Medicaid agencies. .

Stakeholders across the 340B program are already successfully working together on our platform. There are more than 3,500 covered entities across 50 states using Kalderos to prevent errors and create greater transparency across the 340B program. With our cloud-based system, data is accessible, and communication and infrastructure pain points are much easier to identify and solve in a way that benefits everyone—from anywhere, anytime.

We believe collaboration between covered entities and drug manufacturers is imperative to meet the transition to working from home head-on. Our unifying technology is making it happen. As more administrators use our platform, we will make remote work not about replicating in-person tasks online, but about leveraging our new technology to improve productivity and patient outcomes.


Government-administered drug discount programs continue to expand to unanticipated levels, making the need for greater collaboration and transparency more pressing than ever. We offer solutions designed exclusively for both covered entities and drug manufacturers that satisfy each of their requirements. Our user-friendly platform technology, streamlined interfaces and machine learning provide a simplified sign-on experience and easy access to investigate all good faith inquiry claims.

Perhaps your drug company is concerned about revenue leakage or increasing bandwidth to dispute and resolve claims. Maybe your safety net provider is struggling to stay compliant in order to maintain 340B status. The growth and complexity of drug discount programs coupled with increased remote work options demand a reliable digital resource that is available to all stakeholders. It’s time we all get on the same page.

Attendees to the Informa Connect Medicaid Drug Rebate Conference, in Chicago, can learn more during a Kalderos-sponsored panel discussion on “The Dreaded Duplicate Discounts: Collaborating in the New Hybrid Working Landscape,” October 13, 4:50-5:35 p.m. Or, they can also schedule a meeting with Kalderos at the conference.

Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. These posts do not necessarily reflect our opinions and should not be considered endorsements. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (

No comments:

Post a Comment